(Q37886974)

English

Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence

scientific article published on September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

Maarten J. Postma

4

object named as

Maarten J Postma

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Petros Pechlivanoglou

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Robin De Vries

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Simon M G J Daenen

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

1 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

737-751

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

https://scigraph.springernature.com/pub.10.2165/11588370-000000000-00000

0 references

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Invasive fungal infections in hematology: new trends

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Changing patterns and trends in systemic fungal infections

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Trends in invasive fungal infections, with emphasis on invasive aspergillosis

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

The direct cost and incidence of systemic fungal infections

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Newer antifungal agents for invasive fungal infections in patients with haematological malignancy

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Micafungin: a new echinocandin antifungal

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Posaconazole: a broad-spectrum triazole antifungal

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-benefit assessment of antifungal prophylaxis with liposomal amphotericin B in neutropenic patients

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Handling uncertainty in cost-effectiveness models

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Candidaemia in Europe: epidemiology and resistance

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

New and emerging treatments for fungal infections

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Use of indirect and mixed treatment comparisons for technology assessment

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

An overview of fungal infections

1 reference

https://api.crossref.org/works/10.2165%2F11588370-000000000-00000

21 January 2018

Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Invasive Candida infections: the changing epidemiology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infections in haematologic neoplasms: autopsy findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infections in patients with hematological cancer: recent developments

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21657801

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11588370-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37886974&oldid=2111701816"